 Today, I have the pleasure of speaking with Mike from MedEx Health. How are you today? I'm great, Trace. And of course, right now, summer, this is the best time to consider your portfolio for fall, so let's talk about the competitive advantage of getting into MedEx now. Well, as you say, get ready for the fall season, what are we going to put on our wardrobe this year, right? So, I mean, I think we're probably in the best position we've ever been and we're at a tipping point. The last four to six months, we've been dealing with some very large-scale companies. Unfortunately, we're under pretty strong NDAs, so we can't talk a lot about that, but I think we're pretty going to see the fruits of that labor. We've been working very hard to start to roll out under the national scene with some of our, as you know, our technology. And of course, if you're out there and you don't know who MedEx Health is, let Mike tell you why you should get involved in MedEx Health today. Right. So, MedEx Health is a really unique problem, and that is access to a dermatologist. In Canada, there were 565 dermatologists serving 37 million people. Weight times are up to 16 months, in some cases. We can get that down to 72 hours. And it's going to be as simple as going to your doctor if you have a suspicious mole lesion, being referred down to a pharmacy, going from the pharmacy, you take an image. Our technology is the only technology in the world that can look below the skin surface and actually give a dermatologist a perfect view of what they're looking at. It goes from the pharmacy to a dermatologist who does the assessment. And literally, we had one the other day that we caught a melanoma on a Friday. And literally, Monday morning, it was removed. That's the speed at which we can react to something that's deadly inside your body. And of course, many of us who love caused action speed are going to be very impressed by this, Mike. But what I'd love you to do is explain to North America what your friends in Brazil already know. Oh, okay. So we're talking about the revenue model with us. Yes. So our revenue model is a really interesting one. It's really truly a SaaS model. We build the devices for about $800. We sell them for $1,500 to $2,000, depending on the endpoint. But what we really make our money is on the SaaS model. Every time we take a scan, Medex gets between $8 and $10, depending on the jurisdiction and environment we're in. And that doesn't cost us a lot of money to get the scans. So our revenue model is a more interesting part of us. We make a very good margin, a healthy margin, on the scopes that we install in the points of location. But what we really make the money is on the SaaS model, is on the recurring revenue. So take a pharmacy chain, small-sized pharmacy with 1,500 locations. On a 1,500 location pharmacy, we would expect in a year to drive about $8.4 million in revenue, $5.4 that's recurring. That's the exciting part about Medex. And you mentioned Brazil. I'll just speak about Brazil for a second. We're very close to the final stages of getting regulatory approval in Brazil. Once we do that, we have access to a $212 million population base that currently gets detected from melanoma in the later stages where it's really expensive. So we're working with the Ministry of Health there to get at it at the earlier and do the earlier diagnosis. Well I appreciate all of the business updates, which many of us as investors appreciate the bottom-line competitive advantage, but can you just give us some overall statistics on skin cancer for those of you out there that may not understand what a prevailing issue this is in our market? So worldwide there's about 420 million people at risk of melanoma. And it's the fastest growing of the cancers. So the thing about it is it's on the outside of your body. We can detect it. So we should be using the technology, using the infrastructure that's in there now to be able to do that. But it is a very fast growing, why? Look at the amount of heat that we're getting from the climate change and the amount of time people have leisurely outside. And of course I have had some people, young people say to me, millennials who've made a lot of money in the cannabis market, for instance, and say, Yeah, but I can just take my phone and scan it and find out if I have cancer already. Mike, please respond to that. Yeah, that's a real misnomer. You can't do that. And here's the reason why. Your phone's a Class 1 device. There's a whole bunch of issues around privacy. And it really doesn't get you into the food chain. You cannot take a picture on your phone and have it sent to a dermatologist and be properly medically cared for. What we do is work directly and collaboratively with the health care system. So we go into a medical doctor. Your patient file goes along with you. All of the stuff in terms of privacy of information, your images, your follow-on, your care afterwards is all handled within our network, Dermsecure. It's not handled like that with the phone systems, unfortunately. And many of you out there also make investment decisions based on leadership. Mike, I haven't put you on the spot like this before, but we know you have a tremendous background for professional success. Can I ask why you've changed your course in the finance industry and taken a management position at MedEx Health? Well, the operational side of the business is really always intriguing to you. When you raise money, it's one thing. When you actually have to work the gears and the levers to turn a profit, it becomes a little bit more, am I good enough to be able to do that? Have a unique skill set for figure note channel strategies. And that seems to be something that I'm just honed to do. So with a psioscopy, when I saw this device, I said, I really think that I have a good understanding of how to get that to market. And I'm pretty sure investors will get to see that. I'm going to act on that the next few months. Set your computer to MedEx Alert, and Mike, it's so nice to see you again. That's all. It's nice to see you as well. Thank you.